StonvexLoading…
StonvexStonvexStonvexCore line items from IREN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $569.78M | $424.99M | $240.29M | $501.02M |
Operating Income | $-426.33M | $-192.81M | $-76.41M | $17.33M |
Net Income | $-18.62M | $-155.41M | $384.61M | $86.94M |
EPS (Diluted) | $-0.06 | $0.68 | $1.08 | $0.39 |
Total Assets | $7.26B | $7.03B | $4.27B | $2.94B |
Total Liabilities | $4.60B | $4.52B | $1.39B | $1.12B |
Cash & Equivalents | $2.21B | $3.26B | $1.03B | $564.53M |
Free Cash Flow OCF − CapEx | $-1.38B | $-506.00M | $-37.95M | $-327.57M |
Shares Outstanding | 300.37M | 349.83M | 361.68M | 223.25M |